Cargando…
Computational quantification and characterization of independently evolving cellular subpopulations within tumors is critical to inhibit anti-cancer therapy resistance
BACKGROUND: Drug resistance continues to be a major limiting factor across diverse anti-cancer therapies. Contributing to the complexity of this challenge is cancer plasticity, in which one cancer subtype switches to another in response to treatment, for example, triple-negative breast cancer (TNBC)...
Autores principales: | Alkhatib, Heba, Rubinstein, Ariel M., Vasudevan, Swetha, Flashner-Abramson, Efrat, Stefansky, Shira, Chowdhury, Sangita Roy, Oguche, Solomon, Peretz-Yablonsky, Tamar, Granit, Avital, Granot, Zvi, Ben-Porath, Ittai, Sheva, Kim, Feldman, Jon, Cohen, Noa E., Meirovitz, Amichay, Kravchenko-Balasha, Nataly |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583500/ https://www.ncbi.nlm.nih.gov/pubmed/36266692 http://dx.doi.org/10.1186/s13073-022-01121-y |
Ejemplares similares
-
Overcoming resistance to EGFR monotherapy in HNSCC by identification and inhibition of individualized cancer processes
por: Jubran, Maria R., et al.
Publicado: (2022) -
Drug-Induced Resistance and Phenotypic Switch in Triple-Negative Breast Cancer Can Be Controlled via Resolution and Targeting of Individualized Signaling Signatures
por: Vasudevan, Swetha, et al.
Publicado: (2021) -
Overcoming resistance to BRAF(V600E) inhibition in melanoma by deciphering and targeting personalized protein network alterations
por: Vasudevan, S., et al.
Publicado: (2021) -
Decoding cancer heterogeneity: studying patient-specific signaling signatures towards personalized cancer therapy
por: Flashner-Abramson, Efrat, et al.
Publicado: (2019) -
Exploring Alzheimer’s Disease Molecular Variability via Calculation of Personalized Transcriptional Signatures
por: Dagan, Hila, et al.
Publicado: (2020)